Salarius Pharmaceuticals, Inc. (SLRX) Earnings History
Net Loss10 years of earnings data (2015–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Salarius Pharmaceuticals, Inc. (SLRX) Earnings Overview
As of June 21, 2026, Salarius Pharmaceuticals, Inc. (SLRX) reported trailing twelve-month net income of -$5M, reflecting -152268.4% year-over-year growth. The company earned $-10.39 per diluted share over the past four quarters.
Looking at the long-term picture, SLRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2024, representing a new all-time high.
Salarius Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), KROS (-$85M net income, 35.7% margin), TPVG (-$12M net income, 50.6% margin), SLRX has comparable earnings metrics. Compare SLRX vs IMVT →
SLRX Earnings vs Peers
Earnings metrics vs comparable public companies
SLRX Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$6M | +55.5% | -$6M | $-86.85 | - | - |
| 2023 | -$13M | +60.3% | -$13M | $-0.06 | - | - |
| 2022 | -$32M | -147.6% | -$32M | $-221.55 | - | - |
| 2021 | -$13M | -73.7% | -$13M | $-930.00 | - | - |
| 2020 | -$7M | -6.0% | -$8M | $-1500.00 | -140.5% | -148.8% |
| 2019 | -$7M | +68.4% | -$8M | $-6360.00 | -200.2% | -238.5% |
| 2018 | -$22M | +36.3% | -$22M | $-91500.00 | -2615.6% | -2633.7% |
| 2017 | -$34M | +12.8% | -$35M | $-149250.00 | -2701.7% | -2724.6% |
| 2016 | -$39M | -35.5% | -$40M | $-182250.00 | -3907.6% | -3946.5% |
| 2015 | -$29M | - | -$29M | $-19468.80 | - | - |
Download Data
Export SLRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLRX — Frequently Asked Questions
Quick answers to the most common questions about buying SLRX stock.
What is SLRX earnings per share (EPS)?
SLRX trailing twelve-month (TTM) diluted EPS is $-10.39, reflecting -152268.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2024 is available in the table on this page.
What is Salarius Pharmaceuticals, Inc.'s net income?
Salarius Pharmaceuticals, Inc. (SLRX) trailing twelve-month net income is $-5M as of 2024. Earnings declined -152268.4% year-over-year.
Is SLRX profitable?
SLRX is not currently profitable on a TTM basis, reporting a net loss of $-5M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SLRX's earnings growth rate?
SLRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2024.
What are SLRX's profit margins?
Salarius Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -164.0%.
Is SLRX growing earnings?
SLRX earnings are declining — EPS fell -152268.4% year-over-year. TTM net income dropped to $-5M. This contrasts with the 5-year CAGR of N/A.
What was SLRX's best earnings year?
Salarius Pharmaceuticals, Inc.'s highest annual net income on record is $-6M, achieved in fiscal year 2024. Earnings history on this page spans 2015 to 2024 and includes all annual and quarterly figures.
What were SLRX's earnings last quarter?
SLRX's most recent reported quarter was Q3 2025. Net income was $-873467.00 with diluted EPS of $-1.81. For a full breakdown of all quarters, see the quarterly earnings table on this page.